Adewale Adefowoju
Nurse Practitioner · Union, NJNPI 1114153186
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,467 of the $69,650 with a category attached, or 78.2%. AbbVie accounts for 68.0% of it on its own, with 19 other manufacturers making up the rest. Among nurse practitioner clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 568 payments — averaging $122.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$47K
- Teva Pharmaceuticals USA, Inc.$16K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$523
- Johnson & Johnson$512
- plus $3K from 14 others
What the payments were for
- Consulting fees$3300%
- Speaking & faculty fees$54,46778%
- Travel & lodging$3,8776%
- Food & beverage$10,71415%
- Education$2620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 143 | $47,356 |
| Teva Pharmaceuticals USA, Inc. | 113 | $16,229 |
| Alkermes, Inc. | 74 | $1,245 |
| Otsuka America Pharmaceutical, Inc. | 51 | $1,187 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $523 |
| Johnson & Johnson | 29 | $512 |
| Vanda Pharmaceuticals Inc. | 32 | $466 |
| Neuronetics, Inc. | 7 | $415 |
| Neurocrine Biosciences, Inc. | 26 | $389 |
| Lundbeck LLC | 19 | $298 |
| E.r. Squibb & Sons, L.L.C. | 12 | $275 |
| Axsome Therapeutics, Inc. | 5 | $174 |
| Gilead | 1 | $125 |
| Braeburn Inc. | 8 | $125 |
| Viiv Healthcare Company | 1 | $114 |
| Indivior Inc. | 6 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Luye Pharma (USA) Ltd. | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 2 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$45,681
- Austedo XR$14,490
- ABILIFY MAINTENA$375
- ABILIFY ASIMTUFII$375
- NEUROSTAR TMS THERAPY$206
- Yeztugo$125
- AUSTEDO$124
- COBENFY$122
- REXULTI$120
- CABENUVA$114
- Auvelity$109
How this compares
$69,650 in reported general payments places this provider in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 34 | $165,223 |
| Invega SustennaPaliperidone Palmitate | 38 | $105,274 |
| VraylarCariprazine Hcl | 62 | $88,460 |
| Abilify MaintenaAripiprazole | 27 | $72,377 |
| FanaptIloperidone | 19 | $30,741 |
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $24,815 |
| Paliperidone ErPaliperidone | 21 | $6,153 |
| Aripiprazole | 102 | $6,008 |
| Clozapine | 93 | $5,745 |
| Lurasidone Hcl | 67 | $4,916 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 32 | $3,829 |
| Risperidone | 302 | $3,102 |
| Buspirone Hcl | 237 | $3,067 |
| Quetiapine Fumarate | 272 | $2,682 |
| Divalproex Sodium | 113 | $2,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $16,229 | $165,22334 claims |
| Johnson & JohnsonInvega Sustenna | $512 | $105,27438 claims |
| AbbVieVraylar | $47,356 | $88,46062 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,187 | $72,37727 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $466 | $30,74119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.
Other nurse practitioner in Union
- Olufunmilayo IloriUnion$133K
- Nancy BonnetMorristown$407K
- Vanessa CoppolaCloster$205K
- Janice BeitzHaddon Heights$75K
- Sophia KimEnglewood$70K
- Elizabeth FletcherCamden$62K
- Lannae EwingLinwood$39K
- Beth SavageNew Brunswick$34K
- Tina OcchiutoMorristown$25K
- Brandee FonsecaAudubon$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.